Key terms
About BIIB
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest BIIB news
Today
4:58am ET
SPY ETF Update, 3/29/2024
Yesterday
6:11am ET
QQQ ETF Update, 3/28/2024
Mar 25
8:25am ET
Truist Financial Reaffirms Their Buy Rating on Biogen (BIIB)
Mar 22
9:23am ET
Eisai says CHMP oral explanation for lecanemab rescheduled
Mar 20
6:49am ET
QQQ ETF Update, 3/20/2024
Mar 19
8:40am ET
Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX) and Biogen (BIIB)
Mar 13
7:19am ET
Voyager Therapeutics appoints Toby Ferguson as CMO
Mar 13
2:11am ET
Analysts Are Bullish on Top Healthcare Stocks: Biogen (BIIB), Merck & Company (MRK)
Mar 11
9:14am ET
AbCellera gets upfront payment for collaboration with Biogen for antibodies
Mar 11
8:01am ET
Analysts Offer Insights on Healthcare Companies: Onconova Therapeutics (ONTX) and Biogen (BIIB)
Mar 08
9:55am ET
Early notable gainers among liquid option names on March 8th
Mar 06
7:37am ET
Biogen announces interim 6-month data from RESPOND study
Mar 05
11:15pm ET
RBC Capital Keeps Their Buy Rating on Biogen (BIIB)
Feb 27
7:27am ET
RBC Capital Reaffirms Their Buy Rating on Biogen (BIIB)
Feb 23
7:08am ET
Biogen’s QALSODY received positive opinion from CHMP
Feb 22
6:52am ET
Biogen price target lowered to $277 from $355 at Mizuho
Feb 21
3:20am ET
Analysts Are Bullish on These Healthcare Stocks: Johnson & Johnson (JNJ), Vertex Pharmaceuticals (VRTX)
Feb 21
1:43am ET
QQQ ETF Update, 2/21/2024
Feb 20
8:00am ET
Analysts Offer Insights on Healthcare Companies: Cardiol Therapeutics (CRDL), Biogen (BIIB) and Nurix Therapeutics (NRIX)
Feb 20
7:18am ET
Biogen price target lowered to $305 from $310 at Canaccord
Feb 19
1:10am ET
QQQ ETF Update, 2/19/2024
Feb 15
8:38am ET
Sage Therapeutics price target raised to $25 from $23 at Oppenheimer
Feb 15
7:30am ET
Biogen price target lowered to $230 from $255 at Barclays
Feb 15
6:40am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: American Well (AMWL), Biogen (BIIB) and Insmed (INSM)
Feb 15
4:16am ET
Optimistic Outlook for Biogen: Buy Rating Upheld Amid Growth Trajectory and Pipeline Potential
Feb 15
1:41am ET
Analysts Offer Insights on Healthcare Companies: Haemonetics (HAE), Biogen (BIIB) and Axsome Therapeutics (AXSM)
Feb 14
9:35am ET
Scotiabank Sticks to Its Buy Rating for Biogen (BIIB)
Feb 14
9:33am ET
Biogen price target lowered to $275 from $304 at Scotiabank
Feb 14
9:04am ET
Biogen price target lowered to $290 from $295 at Oppenheimer
Feb 14
7:43am ET
Biogen price target lowered to $325 from $350 at Piper Sandler
Feb 14
7:42am ET
Biogen price target lowered to $300 from $305 at Needham
No recent news articles are available for BIIB
No recent press releases are available for BIIB
BIIB Financials
Key terms
Ad Feedback
BIIB Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
BIIB Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range